Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy
In this study, we aimed to evaluate the efficacy and safety of tacrolimus-based treatment for immunoglobulin A nephropathy (IgAN). We retrospectively reviewed 127 adult patients with primary IgAN with 24 h urine total protein quantity (24 h UTP) ≥ 1 g and serum creatinine ≤3 mg/dL. All patients were...
Main Authors: | Lijuan Zhao, Yanyan Yang, Hao Xu, Wei Leng, Guoshuang Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1189608/full |
Similar Items
-
Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials
by: Zheng Zhang, et al.
Published: (2019-08-01) -
Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study
by: Chen Tang, et al.
Published: (2020-11-01) -
Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades
by: Byeong Yun Yang, et al.
Published: (2012-09-01) -
IgA Vasculitis Complicated by Both CMV Reactivation and Tuberculosis
by: Małgorzata Mizerska-Wasiak, et al.
Published: (2021-07-01) -
Management of IgA Nephropathy in Pediatric Patients
by: Sophie Schroda, et al.
Published: (2022-05-01)